FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site
- 26 March 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 40 (5) , 1275-1288
Abstract
Objective: Recent studies showed that FVIIa (factor VIIa), upon binding to EPCR (endothelial cell protein C receptor), elicits endothelial barrier stabilization and anti-inflammatory effects via activation of PAR (protease-activated receptor)-1–mediated signaling. It is unknown whether FVIIa induces PAR1-dependent cytoprotective signaling through cleavage of PAR1 at the canonical site or a noncanonical site, similar to that of APC (activated protein C). Approach and Results: Mouse strains carrying homozygous R41Q (canonical site) or R46Q (noncanonical site) point mutations in PAR1 (QQ41-PAR1 and QQ46-PAR1 mice) were used to investigate in vivo mechanism of PAR1-dependent pharmacological beneficial effects of FVIIa. Administration of FVIIa reduced lipopolysaccharide-induced inflammation, barrier permeability, and VEGF (vascular endothelial cell growth factor)-induced barrier disruption in wild-type (WT) and QQ46-PAR1 mice but not in QQ41-PAR1 mice. In vitro signaling studies performed with brain endothelial cells isolated from WT, QQ41-PAR1, and QQ46-PAR1 mice showed that FVIIa activation of Akt (protein kinase B) in endothelial cells required R41 cleavage site in PAR1. Our studies showed that FVIIa cleaved endogenous PAR1 in endothelial cells, and FVIIa-cleaved PAR1 was readily internalized, unlike APC-cleaved PAR1 that remained on the cell surface. Additional studies showed that pretreatment of endothelial cells with FVIIa reduced subsequent thrombin-induced signaling. This process was dependent on β-arrestin1. Conclusions: Our results indicate that in vivo pharmacological benefits of FVIIa in mice arise from PAR1-dependent biased signaling following the cleavage of PAR1 at the canonical R41 site. The mechanism of FVIIa-induced cytoprotective signaling is distinctly different from that of APC. Our data provide another layer of complexity of biased agonism of PAR1 and signaling diversity.Keywords
This publication has 39 references indexed in Scilit:
- Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46Blood, 2012
- Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffoldsProceedings of the National Academy of Sciences, 2011
- Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protectionBlood, 2011
- Thromboembolic Events With Recombinant Activated Factor VII in Spontaneous Intracerebral HemorrhageStroke, 2010
- Caveolae are required for protease-selective signaling by protease-activated receptor–1Proceedings of the National Academy of Sciences, 2009
- Activated protein C–cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombinBlood, 2008
- The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cellsBlood, 2007
- Endothelial Cell Protein C Receptor Acts as a Cellular Receptor for Factor VIIa on EndotheliumJournal of Biological Chemistry, 2007
- Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cellsProceedings of the National Academy of Sciences, 2007
- Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patientCurrent Surgery, 2003